Navigation Links
ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
Date:9/8/2009

IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred(TM) (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

In the first study, ISTA evaluated the antimicrobial equivalence between T-Pred and a tobramycin-containing reference product. In vitro tests were conducted to compare the kill rate of T-Pred with the kill rate of the reference product for each of the micro-organisms listed in the reference product's package insert as well as additional micro-organisms specified by the Food and Drug Administration (FDA). ISTA successfully demonstrated the antimicrobial bioequivalence of T-Pred to the reference product in each of the 26 required tests.

The second study was a Phase 3 clinical study designed to determine the bioequivalence of prednisolone concentrations between T-Pred and a reference product containing prednisolone acetate 1.0%. The multi-center, randomized, double-masked study enrolled 172 patients undergoing bilateral cataract removal. Patients served as their own internal control in this study, receiving one drop of either T-Pred or the prednisolone reference product prior to cataract extraction. Aqueous humor sampling was performed at one of four assigned time points. In order to demonstrate the bioequivalence of the two products, the ratio of calculated prednisolone values in aqueous humor needed to fall between 80% and 125%, with a 90% confidence interval for the rat
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
2. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
3. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
4. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
5. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
6. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
7. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
8. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
9. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013   NextDocs announced today ... clinical research organization, at DIA 2013 , the ... will present case studies that explore best practices for ... electronic trial master file (eTMF) systems. ... present alongside Krystyna Kowalczyk , executive vice president ...
(Date:6/19/2013)... CLARA, Calif. , June 19, 2013 /PRNewswire/ ... control solutions for life sciences process applications, announced ... glass bioreactors for upstream cell culture and fermentation.  ... a new product family of Finesse bioreactors and ... and cGMP applications.  They are fully compatible with ...
(Date:6/19/2013)... India , June 19, 2013 ... Bureau has recently added DrugPatentWatch to ... ( http://www.bharatbook.com/drugpatentwatch-tour.pdf )      ... provides comprehensive information on pharmaceutical, drug ... information supports the critical business functions ...
Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3
... 13 Otix Global, Inc. (Otix) (Nasdaq: OTIX ... today announced that it has decided to discontinue its operations ... decision, Sam Westover, Chairman and CEO of Otix stated, "the ... stability of our business and, as a result, we have ...
... Applied Precision is sending its Mobile ... and research centers.   The Applied Precision ... 40-foot coach bus.  The lab is equipped with Applied ... a wet lab.  New this year is a special ...
Cached Medicine Technology:Otix Global, Inc. to Discontinue German Operations 2Otix Global, Inc. to Discontinue German Operations 3Applied Precision's Mobile Imaging Lab Hits the Road for a Cross-Country Journey 2
(Date:6/19/2013)... medicine and trauma surgery have had a significant ... immediately after major injuries, including burns. Patients ... now are at greatest risk from infections ... sepsis or from inflammation-induced multiorgan failure. ... (MGH) investigators that measures the movement of key ...
(Date:6/19/2013)... (June 19, 2013) In what is believed to ... most common form of hereditary dystonia a movement ... in deep brain stimulation report good success rates and ... the Movement Disorders Program at Cedars-Sinai Medical Center,s Department ... the Division of Neurosurgery at Beth Israel Deaconess Medical ...
(Date:6/19/2013)... The results of three important studies have been published ... journal of the Congress of Neurological Surgeons . ... & Wilkins , a part of Wolters Kluwer ... learning" using artificial neural networks (ANNs) may improve the ... cancers. Another study in the June Neurosurgery ...
(Date:6/19/2013)... Ann Arbor, Mich. Children had half as ... had evening office hours on five or more days ... experts at C.S. Mott Children,s Hospital and Johns Hopkins ... month in The Journal of Pediatrics and ... , "These findings are an important step in understanding ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
Breaking Medicine News(10 mins):Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... as a key resource for finding the best Government and nonprofit ... straightforward and credible information catalogued on the site. But it is ... for disease prevention and wellness information interactive and action oriented. ... ...
... Amoena, the worldwide leader of post-breast surgery ... Hannah Collection, the industry,s first post-surgical garments ... ease discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole ...
... ORTHOCON¿ Inc. today announced that Paul R. Sohmer, ... Executive Officer. The company also announced the closing of ... healthcare investors. ORTHOCON is developing innovative implantable devices ... platform may be leveraged to deliver a variety of ...
... high marks on intentions for good nutrition but lack ... no surprise that with the current economic conditions, three-quarters ... healthy eating is largely dependent on what food families ... family pantries, fridges, and freezers, Rutgers University ...
... 8 Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) ... BG Medicine (BGM) in its Phase 2 clinical safety ... this collaboration, BGM will measure levels of Galectin-3 in ... for cardiac remodeling associated with advanced stages of heart ...
... April 8 The College of American Pathologists (CAP), ... and deeming authority under the Clinical Laboratory Improvement Amendments ... Services (CMS) since 1995, has been notified that it ... a six-year period, the longest period available for this ...
Cached Medicine News:Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2
... more efficient way to control thermoregulation. ... operated patient warming system, provides hospitals, ... a compact and better way to ... process. Its unique design combines functionality ...
... WarmAir® system from CSZ safely provides effective ... of the unique patented design of our ... lower velocity blower which supplies gently moving, ... that may spread contaminants to your patient ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: